5 Key Takeaways

• 1

  Tyrosine kinase inhibitors (TKIs) may revolutionize treatment for wet AMD and diabetic retinopathy, addressing significant vision loss causes.

• 2

  Current therapies involve frequent anti-VEGF injections, which can lead to patient self-discontinuation due to burden and adverse effects.

• 3

  TKIs target multiple pathways involved in retinal diseases, offering a broader therapeutic impact compared to traditional anti-VEGF agents.

• 4

  Several TKIs are in clinical trials, exploring various administration routes and innovative delivery methods for enhanced efficacy.

• 5

  Promising results from trials indicate TKIs could reduce treatment frequency and improve patient outcomes in retinal disease management.